Orion Oyj
OMXH:ORNBV
Orion Oyj
Other Operating Expenses
Orion Oyj
Other Operating Expenses Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other Operating Expenses | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
O
|
Orion Oyj
OMXH:ORNBV
|
Other Operating Expenses
€9.6m
|
CAGR 3-Years
51%
|
CAGR 5-Years
24%
|
CAGR 10-Years
18%
|
|
|
H
|
Herantis Pharma Oyj
OMXH:HRTIS
|
Other Operating Expenses
€1.5m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Orion Oyj
Glance View
Orion Oyj, a stalwart in the pharmaceutical industry, has carved out a significant niche for itself since its inception in Finland. The company was founded in 1917, and over the years, it has evolved into a crucial player in the global medical landscape. As a fully integrated pharmaceutical entity, Orion’s operations encompass everything from research and development to manufacturing and distribution. Its primary areas of focus include the development of therapies for central nervous system disorders, oncology, and respiratory diseases, as well as a selection of veterinary medicines and active pharmaceutical ingredients (APIs). This comprehensive approach enables Orion to maintain control over the entire drug production pipeline, ensuring quality and innovation are at the forefront of its mission. Orion's business strategy revolves around a robust combination of proprietary innovations and strategic partnerships. The company invests heavily in R&D, dedicating a substantial portion of its revenue to discovering and developing new drugs. By doing so, it fortifies its product pipeline, ensuring a steady influx of new offerings that cater to unmet medical needs, fostering a competitive edge in the market. Additionally, Orion supplements its earnings through collaborations with other pharmaceutical giants, expanding its market reach and sharing resources to mitigate risks associated with the costly drug development process. Through this dual approach of in-house excellence and collaborative ventures, Orion Oyj effectively sustains its financial health, continually fueling its growth and ensuring it remains a formidable force in the international pharmaceutical arena.
See Also
What is Orion Oyj's Other Operating Expenses?
Other Operating Expenses
9.6m
EUR
Based on the financial report for Dec 31, 2024, Orion Oyj's Other Operating Expenses amounts to 9.6m EUR.
What is Orion Oyj's Other Operating Expenses growth rate?
Other Operating Expenses CAGR 10Y
18%
Over the last year, the Other Operating Expenses growth was 78%. The average annual Other Operating Expenses growth rates for Orion Oyj have been 51% over the past three years , 24% over the past five years , and 18% over the past ten years .
You don't have any saved screeners yet